<DOC>
	<DOCNO>NCT02780700</DOCNO>
	<brief_summary>The objective Phase II study ass efficacy safety nintedanib alone combination capecitabine patient refractory mCRC failure least 2 line standard treatment</brief_summary>
	<brief_title>Nintedanib Alone Combination With Capecitabine Refractory Metastatic Colorectal Cancer LUME-Colon 2</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<criteria>Inclusion criterion : Histologically cytologically confirm colorectal adenocarcinoma Metastatic locally advance disease amenable curative surgery and/or radiotherapy Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; = 1 At least one measurable lesion accord RECIST 1.1 Previously treat following : fluoropyrimidine , ( e.g . 5FU , capecitabine TAS102 ) ; oxaliplatin : Patients treat oxaliplatin adjuvant setting progress within 6 month completion adjuvant therapy must treat oxaliplatin metastatic disease ; Irinotecan ; Vascular Endothelial Growth Factor ( VEGF ) direct treatment ( e.g . bevacizumab , aflibercept , ramucirumab regorafenib ) ; cetuximab panitumumab patient KRas wt Ras wt tumor Minimal time interval 3 week last administration Colorectal Cancer ( CRC ) treatment ( cytotoxics target agent ) start trial therapy Adequate liver kidney function Further inclusion criterion apply Exclusion criterion : Prior treatment nintedanib . Any investigational agent receive within 3 week prior randomization Known hypersensitivity intolerability trial drug excipients History malignancy last 5 year , particular could interfere interpretation result . Patients adequately treat basal squamous cell skin cancer cervix carcinoma early stage cancer treat curatively eligible History severe unexpected reaction fluoropyrimidine therapy excipients Known dihydropyrimidine dehydrogenase ( DPD ) deficiency Treatment sorivudine chemically related analogue , brivudine Serious concomitant disease medical condition affect compliance trial requirement consider relevant evaluation efficacy safety trial drug , neurologic , psychiatric , infectious disease active ulcer ( gastrointestinal tract , skin ) laboratory abnormality may increase risk associate trial participation trial drug administration , judgment investigator would make patient inappropriate entry trial Major injury and/or surgery bone fracture within 4 week trial inclusion ( sign Informed Consent ) , plan surgical procedure trial period Significant cardiovascular disease ( i.e . uncontrolled hypertension , unstable angina , history myocardial infarction within past 6 month trial inclusion , congestive heart failure &gt; NYHA II ) History severe hemorrhagic thromboembolic event past 6 month ( exclude central venous catheter thrombosis peripheral deep vein thrombosis ) . Known inherited predisposition bleed thrombosis Bleeding thrombotic disorder require anticoagulant therapy warfarin , similar agent require therapeutic INR monitoring ( treatment low molecular weight heparin and/or heparin flush need maintenance indwell intravenous device allow ) Inflammatory bowel disease serious medical condition increase risk perforation bleed accord investigator 's judgment Gastrointestinal disorder abnormality would interfere absorption study drug Patient brain metastasis symptomatic and/or require therapy . Patients previously treat stable brain metastasis allow Further exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>